Aquestive Therapeutics, Inc. AQST
Set alert
3.89 USD -0.15 -3.71%
At close · Oct 30
3.95 +0.06 +1.42%
After hours · Oct 30, 7:43 PM ET
3.86 Day range 4.05
2.95 52-week range 6.82
- YTD
- -39.78%
- 1 year
- -41.59%
- Open
- 4.01
- Prev close
- 4.04
- Mkt cap
- 488.24M
- Vol
- 2.42M
- Avg vol
- 2.73M
- EPS
- -0.66
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.86
- High
- 4.05
- Forward P/E
- -5.87
- Beta
- 2.82
- Short ratio
- 6.37
- Inst. own
- 55.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 4.68
- 200-d avg
- 4.02
- 1y target
- 10.83
MAX chart
Events in this range
- Mar 5, 2024Earnings: -0.12; estimate -0.08; surprise -50%
- May 7, 2024Earnings: -0.17; estimate -0.09; surprise -88.89%
- May 7, 2024Earnings: —; estimate -0.09; surprise —%
- Aug 6, 2024Earnings: -0.03; estimate -0.11; surprise 72.73%
- Aug 6, 2024Earnings: —; estimate -0.11; surprise —%
- Oct 25, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Oct 25, 2024Rating: Leerink Partners · Outperform → Outperform
- Nov 4, 2024Earnings: -0.13; estimate -0.12; surprise -8.33%
- Nov 6, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 11, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 17, 2024Rating: Cantor Fitzgerald · — → Overweight
- Dec 20, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (129)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Mar 2, 2026 | 8 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 8, 2025 | 10 months ago |
| SMA: Bullish | Dec 1, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| RSI: Overbought | Oct 6, 2025 | 1 year ago |
| RSI: Overbought | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| RSI: Overbought | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| MACD: Buy Signal | May 26, 2025 | 1 year ago |
| MACD: Sell Signal | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| MACD: Buy Signal | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| SMA: Bearish | May 27, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 8, 2024 | 2 years ago |
| RSI: Overbought | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Nov 20, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 20, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Sep 18, 2023 | 3 years ago |
| SMA: Bullish | Sep 11, 2023 | 3 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| SMA: Bearish | Aug 28, 2023 | 3 years ago |
| SMA: Bullish | Aug 21, 2023 | 3 years ago |
| SMA: Bearish | Aug 14, 2023 | 3 years ago |
| SMA: Bullish | Jul 24, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jun 19, 2023 | 3 years ago |
| RSI: Overbought | May 1, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bullish | Mar 20, 2023 | 3 years ago |
| SMA: Bearish | Jan 16, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jul 18, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 11, 2022 | 4 years ago |
| RSI: Oversold | Apr 25, 2022 | 4 years ago |
| SMA: Bearish | Mar 28, 2022 | 4 years ago |
| SMA: Bullish | Mar 21, 2022 | 4 years ago |
| MACD: Sell Signal | Dec 27, 2021 | 4 years ago |
| SMA: Bearish | Dec 20, 2021 | 4 years ago |
| SMA: Bearish | Dec 20, 2021 | 4 years ago |
| SMA: Bullish | Dec 13, 2021 | 4 years ago |
| SMA: Bearish | Nov 29, 2021 | 4 years ago |
| SMA: Bullish | Oct 18, 2021 | 5 years ago |
| SMA: Bullish | Oct 18, 2021 | 5 years ago |
| SMA: Bearish | Oct 4, 2021 | 5 years ago |
| SMA: Bearish | Oct 4, 2021 | 5 years ago |
| SMA: Bullish | Aug 30, 2021 | 5 years ago |
| SMA: Bullish | Aug 23, 2021 | 5 years ago |
| SMA: Bearish | Aug 16, 2021 | 5 years ago |
| SMA: Bullish | Aug 9, 2021 | 5 years ago |
| SMA: Bearish | Jul 5, 2021 | 5 years ago |
| MACD: Buy Signal | Jun 14, 2021 | 5 years ago |
| SMA: Bullish | Jun 7, 2021 | 5 years ago |
| SMA: Bearish | Feb 15, 2021 | 5 years ago |
| SMA: Bullish | Feb 8, 2021 | 5 years ago |
| SMA: Bearish | Dec 28, 2020 | 5 years ago |
| SMA: Bearish | Dec 28, 2020 | 5 years ago |
| MACD: Sell Signal | Dec 28, 2020 | 5 years ago |
| MACD: Buy Signal | Dec 7, 2020 | 5 years ago |
| SMA: Bullish | Nov 16, 2020 | 5 years ago |
| SMA: Bullish | Nov 9, 2020 | 5 years ago |
| MACD: Sell Signal | Oct 5, 2020 | 6 years ago |
| SMA: Bearish | Sep 28, 2020 | 6 years ago |
| SMA: Bearish | Sep 28, 2020 | 6 years ago |
| RSI: Overbought | Aug 17, 2020 | 6 years ago |
| SMA: Bullish | Jul 20, 2020 | 6 years ago |
| SMA: Bearish | Jun 29, 2020 | 6 years ago |
| SMA: Bullish | May 4, 2020 | 6 years ago |
| MACD: Buy Signal | Apr 27, 2020 | 6 years ago |
| SMA: Bullish | Apr 13, 2020 | 6 years ago |
| MACD: Sell Signal | Jan 20, 2020 | 6 years ago |
| SMA: Bearish | Jan 13, 2020 | 6 years ago |
| SMA: Bearish | Jan 13, 2020 | 6 years ago |
| SMA: Bullish | Jan 6, 2020 | 6 years ago |
| SMA: Bearish | Dec 9, 2019 | 6 years ago |
| RSI: Overbought | Nov 25, 2019 | 6 years ago |
| SMA: Bullish | Nov 4, 2019 | 6 years ago |
| SMA: Bullish | Oct 28, 2019 | 7 years ago |
| SMA: Bearish | Jul 8, 2019 | 7 years ago |
| SMA: Bullish | Jul 1, 2019 | 7 years ago |
| SMA: Bearish | Apr 1, 2019 | 7 years ago |
| SMA: Bullish | Mar 25, 2019 | 7 years ago |
| SMA: Bearish | Mar 11, 2019 | 7 years ago |
| SMA: Bullish | Feb 25, 2019 | 7 years ago |
| SMA: Bearish | Jan 28, 2019 | 7 years ago |
| SMA: Bullish | Jan 21, 2019 | 7 years ago |
| RSI: Oversold | Dec 17, 2018 | 7 years ago |
| SMA: Bearish | Nov 19, 2018 | 7 years ago |
| SMA: Bullish | Oct 29, 2018 | 8 years ago |
| SMA: Bearish | Oct 1, 2018 | 8 years ago |
Key statistics
- Market cap
- 320.95M
- Enterprise value
- 291.78M
- Trailing P/E
- 0.00
- Forward P/E
- -5.87
- PEG ratio
- 0.00
- Price / sales
- 5.45
- Price / book
- 0.00
- EPS (TTM)
- -0.45
- Beta
- 2.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -59.75%
- Revenue (TTM)
- 58.90M
- Revenue growth
- 4.20%
- Free cash flow
- -12.32M
- Total cash
- 77.89M
- Total debt
- 36.87M
- Return on equity
- 0.00%
- Shares outstanding
- 91.18M
- Short % of float
- 13.33%
- 50-day average
- 4.68
- 200-day average
- 4.02
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.83 +178.5% upside
Now 3.89
- Target (low)
- 5.50
- Target (mean)
- 10.83
- Target (high)
- 17.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy4
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.1325.
Financials — quick view
AQST Revenue — quarterly 13.82M
AQST Net income — quarterly -22.86M
AQST EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.12 | -0.13 | -0.01 | -8.33% |
| Aug 6, 2024 | Jun 1, 2024 | -0.11 | -0.03 | +0.08 | +72.73% |
| Aug 6, 2024 | Jun 1, 2024 | -0.11 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.09 | -0.17 | -0.08 | -88.89% |
| May 7, 2024 | Mar 1, 2024 | -0.09 | — | — | — |
| Mar 5, 2024 | Dec 1, 2023 | -0.08 | -0.12 | -0.04 | -50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 17, 2024 | Cantor Fitzgerald | init | — | Overweight |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 25, 2024 | Leerink Partners | main | Outperform | Outperform |
| Oct 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- aquestive.com
News
- Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
- Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $105,500.00 in Stock
- Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade
- FDA Accepts Aquestive Therapeutics’ Anaphylm NDA Resubmission; PDUFA Goal Action Date Set For March 16, 2027
- Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
- Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
- Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027
- Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop
- Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
- Aquestive Therapeutics, Inc. $AQST Shares Sold by Squarepoint Ops LLC
Your note
Sign in to keep a note on AQST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARBER DANIEL | Chief Executive Officer | Stock Award(Grant) | Mar 6, 2024 | 883,302 |
| BOYD PETER E | Officer | Stock Award(Grant) | Mar 6, 2024 | 245,998 |
| BRAENDER LORI J | General Counsel | Stock Award(Grant) | Mar 6, 2024 | 323,761 |
| BRATTON DOUGLAS K | Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Dec 1, 2024 | 0 |
| JUNG CASSIE | Chief Operating Officer | Sale | Nov 25, 2024 | 0 |
| KORCZYNSKI SHERRY | Officer | Stock Award(Grant) | Jun 6, 2024 | 25,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bratton Capital Management, LP | 10.76% | 9,810,958 | 34.53M | Sep 29, 2024 |
| Blackrock Inc. | 6.39% | 5,823,077 | 20.50M | Sep 29, 2024 |
| VR Adviser, LLC | 6.09% | 5,555,555 | 19.56M | Sep 29, 2024 |
| Vanguard Group Inc | 4.68% | 4,263,796 | 15.01M | Sep 29, 2024 |
| Franklin Resources, Inc. | 3.03% | 2,766,542 | 9.74M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 1.97% | 1,796,750 | 6.32M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.64% | 2,404,170 | 8.46M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.11% | 1,920,925 | 6.76M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.23% | 1,121,385 | 3.95M | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.09% | 993,800 | 3.50M | Jul 30, 2024 |
| Fidelity Small Cap Index Fund | 0.83% | 760,525 | 2.68M | Aug 30, 2024 |
| Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF | 0.82% | 750,545 | 2.64M | Oct 30, 2024 |